AM
AMPH.US Amphastar P
- Market cap
- USD 1.25B
- P/E
- 13.5x
- P/B
- 1.51x
- ROE
- 12.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AMPH.US undervalued?
Graham numberAMPH.US trades 4.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amphastar P fundamental analysis
No fundamental analysis for Amphastar P yet.
Amphastar P stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxap…
Full company profileAmphastar P financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amphastar P annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 255M | 240M | 295M | 322M | 350M | 438M | 499M | 644M | 732M | 720M | 750M |
| Gross Profit | 104M | 90.8M | 107M | 132M | 143M | 200M | 249M | 351M | 374M | 356M | 351M |
| Operating Income | 15.7M | -895K | -8.62M | -39.0K | 11.0M | 69.9M | 107M | 197M | 205M | 140M | 139M |
| EBITDA | 30.3M | 17.9M | 7.89M | 21.1M | 30.2M | 110M | 146M | 240M | 277M | 212M | 222M |
| Net Income | 10.5M | 4.51M | -5.74M | 48.9M | 1.40M | 62.1M | 91.4M | 138M | 160M | 98.1M | 99.4M |
| EPS | 0.22 | 0.09 | -0.12 | 0.98 | 0.03 | 1.25 | 1.74 | 2.60 | 3.06 | 2.03 | 2.29 |
| Balance Sheet | |||||||||||
| Total Assets | 428M | 455M | 514M | 587M | 631M | 672M | 742M | 1.51B | 1.58B | 1.63B | 1.71B |
| Total Liabilities | 98.5M | 117M | 149M | 159M | 183M | 226M | 213M | 873M | 845M | 840M | 897M |
| Shareholders' Equity | 329M | 337M | 332M | 381M | 402M | 446M | 529M | 639M | 732M | 789M | 815M |
| Cash & Short-term Investments | 72.9M | 68.2M | 89.2M | 89.5M | 106M | 137M | 176M | 257M | 222M | 283M | 231M |
| Total Debt | 37.7M | 47.2M | 50.2M | 66.6M | 67.3M | 105M | 103M | 624M | 651M | 656M | 692M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 38.6M | 39.2M | 38.2M | 41.8M | 57.3M | 98.0M | 89.2M | 184M | 213M | 156M | 190M |
| Capital Expenditure | 21.4M | 35.1M | 46.8M | 41.6M | 33.9M | 27.5M | 24.0M | 38.2M | 41.0M | 34.9M | 37.4M |
| Free Cash Flow | 17.2M | 4.11M | -8.62M | 207K | 23.4M | 70.5M | 65.1M | 145M | 172M | 121M | 153M |
| Ratios | |||||||||||
| ROE | 3.2% | 1.3% | -1.7% | 12.8% | 0.3% | 13.9% | 17.3% | 21.5% | 21.8% | 12.4% | 12.2% |
| ROA | 2.5% | 1.0% | -1.1% | 8.3% | 0.2% | 9.2% | 12.3% | 9.1% | 10.1% | 6.0% | 5.8% |
| Net Profit Margin | 4.1% | 1.9% | -1.9% | 15.2% | 0.4% | 14.2% | 18.3% | 21.3% | 21.8% | 13.6% | 13.2% |
| Debt to Equity | 0.11x | 0.14x | 0.15x | 0.17x | 0.17x | 0.23x | 0.19x | 0.98x | 0.89x | 0.83x | 0.85x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amphastar P dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 454M | 8.57 | 330.1% |
| 2022 | USD 15.7M | 0.30 | 17.1% |
| 2021 | USD 15.9M | 0.32 | 25.6% |
| 2020 | USD 23.2M | 0.47 | 1,651.1% |
| 2019 | - | - | - |
| 2018 | USD 20.3M | 0.44 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Amphastar P
- Insiders 31.01%
- Institutions 67.62%
- Public & others 1.37%
- Shares outstanding 42.6M
- Free float 31.4M
Top funds holding AMPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.90M | 4.45% | +0.06% | Oct 2026 |
| Avantis US Small Cap Value ETF | 1.46M | 3.41% | +0.92% | Oct 2026 |
| FullerThaler Behavioral Sm-Cp Eq R6 | 903K | 2.12% | -36.82% | Jun 2026 |
| DFA U.S. Small Cap Value I | 861K | 2.02% | +44.45% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 847K | 1.99% | -19.81% | Sep 2026 |
| iShares Russell 2000 ETF | 817K | 1.92% | 0.00% | Oct 2026 |
| DFA U.S. Targeted Value I | 316K | 0.74% | +2.32% | Sep 2026 |
| Fidelity Small Cap Index | 306K | 0.72% | -13.53% | Aug 2026 |
| iShares Russell 2000 Value ETF | 304K | 0.71% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 287K | 0.67% | -0.05% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 279K | 0.65% | +2.88% | Oct 2026 |
| Vanguard Tax-Managed Small Cap Adm | 269K | 0.63% | 0.00% | Sep 2026 |
| Dimensional US Small Cap Value ETF | 265K | 0.62% | +0.07% | Sep 2026 |
| Dimensional US Targeted Value ETF | 215K | 0.50% | +0.03% | Oct 2026 |
| DFA U.S. Small Cap I | 210K | 0.49% | 0.00% | Sep 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 196K | 0.46% | +0.23% | Oct 2026 |
| DFA US Micro Cap I | 192K | 0.45% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 188K | 0.44% | +1.17% | Sep 2026 |
| Applied Finance Explorer Institutional | 181K | 0.42% | +3.07% | Jul 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 175K | 0.41% | 0.00% | Oct 2026 |
Top institutions holding AMPH.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.22M | 12.28% | -3.62% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.38M | 5.60% | +3.38% | Sep 2026 |
| State Street Corp | 1.64M | 3.86% | +2.15% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.48M | 3.48% | -4.00% | Jun 2026 |
| American Century Companies Inc | 1.18M | 2.77% | +15.63% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.07M | 2.51% | +3.97% | Jun 2026 |
| Geode Capital Management, LLC | 970K | 2.28% | -0.70% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 949K | 2.23% | -31.96% | Jun 2026 |
| D. E. Shaw & Co LP | 887K | 2.09% | +33.28% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 810K | 1.90% | +2.76% | Jun 2026 |
| LSV Asset Management | 642K | 1.51% | -1.49% | Jun 2026 |
| Renaissance Technologies Corp | 525K | 1.23% | -5.20% | Jun 2026 |
| The Goldman Sachs Group Inc | 505K | 1.19% | +53.42% | Jun 2026 |
| Systematic Financial Management LP | 437K | 1.03% | -3.43% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 435K | 1.02% | +3.45% | Jun 2026 |
| UBS Group AG | 393K | 0.92% | -6.46% | Jun 2026 |
| HRT FINANCIAL LLC | 388K | 0.91% | +589.79% | Jun 2026 |
| Bridge City Capital, LLC | 384K | 0.90% | +13.34% | Sep 2026 |
| Denali Advisors LLC | 376K | 0.88% | +41.09% | Jun 2026 |
| Northern Trust Corp | 371K | 0.87% | -0.35% | Jun 2026 |
Amphastar P company profile
- Company name
- Amphastar P
- Ticker
- AMPH.US
- Exchange
- USA Stocks
- Listed since
- Jun 25, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,976
- Fiscal year end
- December
- Address
- 11570 6th Street, Rancho Cucamonga, CA, United States, 91730
- Phone
- 909 980 9484
- Website
- amphastar.com
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar P management
7- Dr. Ziping Luo Ph.D.Chairman of the Board, Chief Scientist & COO · born 1950
- Dr. Yongfeng Zhang Ph.D.Co-Founder, President, CEO, Chief Scientific Officer & Director · born 1947
- Mr. William J. Peters M.B.A.CFO, Executive VP of Finance, Treasurer & Director · born 1968
- Mr. Jacob Liawatidewi M.B.A.Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director · born 1974
- Mr. Rong Zhou M.S.Senior EVP of Production & EVP of Scientific Affairs · born 1959
- Mr. Dan Dischner M.B.A.Senior Vice President of Human Resources & Corporate Communication
- Tony Marrs M.B.A., M.P.H., M.S.Executive VP of Regulatory Affairs & Clinical Operations